Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...

The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...

*仅供医学专业人士阅读参考把肿瘤微环境内因抗原慢性刺激转入耗竭状态的CD8+T细胞“叫醒”，让它们重新活化为效应CD8+T细胞，是PD-1/L1抑制剂为代表的现有免疫治疗起效的关键，但实话实说，激活处在耗竭状态的CD8+T细胞，在奇点糕眼里总觉得有点 ...

*仅供医学专业人士阅读参考在目前已经获批的各种免疫联合治疗方案里，PD-1/L1抑制剂和CTLA-4抑制剂组成的“双免疫方案”，经常给奇点糕一种双刃剑的感觉，一方面它们确实取得了不少关键临床研究的成功，对非小细胞肺癌（NSCLC）、肝癌等常见实体瘤有 ...

This valuable study reports on a novel role of PD-1 in early T cell differentiation, showing that PD-1 stimulation impairs Th2 differentiation more effectively than that of Th1, with implications for ...

Immatics (IMTX) has received a new Buy rating, initiated by Piper Sandler analyst, Joseph Catanzaro. Joseph Catanzaro has given his Buy rating ...

The causes of MS are still incompletely understood. In a study of identical twins, a team led by PD Dr. Lisa Ann Gerdes ...

The expansion of CAR T cells peaked on day 10 (47 CAR T cells per microliter) (Figure 1A). The initial clinical course after CAR T-cell therapy was unremarkable, with grade 1 cytokine release ...

BioNTech SE (Formerly TRON—Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH), Mainz, Germany.